From the floor in Tianjin: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The archive — 2025
Page 36 of 68 of this archive, newest first.
STEP 4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Gastric emptying is a mechanism, not a side effect
The central effects are not a bonus. On the current evidence they are the principal mechanism of weight loss.
Chain of custody, and where it begins
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
A shortage listing ends. 24 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Germany declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why your laboratory interval differs from the one in the textbook
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
Storage after reconstitution, and the evidence behind the numbers
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
The eighteenth month, and the conversation that should have happened in the third
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What an 18% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Hong Kong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a QST orforglipron lot at 98.0%, against 94.2% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
From the floor in Wuhan: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 30-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
Twenty-eight days is a number from somebody else’s product
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
One method is one opinion
Where two methods disagree, the conservative convention is to report the lower figure. It is not universal, and whether a laboratory follows it belongs on the report.
Falling ferritin is not always falling iron
The panel drawn during a week of vomiting is measuring the vomiting.
VendorInvestigate result on a Changsha liraglutide lot lands 3.2 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Saudi Arabia pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
What the older diet-and-exercise trials found in the hip
A plausible mechanism, a measurable change, and no outcome data. This is what an open question looks like.
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.